CD4+ T Cells and Cytokines in the Pathogenesis of Acquired Myasthenia Gravis
暂无分享,去创建一个
[1] Monica Milani,et al. Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.
[2] H. Eng,et al. Human monoclonal immunoglobulins that bind the human acetylcholine receptor , 1987, European journal of immunology.
[3] J. Ihle. The Stat family in cytokine signaling. , 2001, Current opinion in cell biology.
[4] H. Link,et al. Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. , 1997, Clinical immunology and immunopathology.
[5] A. O’Garra,et al. Cytokines induce the development of functionally heterogeneous T helper cell subsets. , 1998, Immunity.
[6] F. Shi,et al. Natural killer cells determine the outcome of B cell–mediated autoimmunity , 2000, Nature Immunology.
[7] Chuan-zhen Lu,et al. Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy. , 2004, Clinical immunology.
[8] R. Ruff,et al. The Myasthenic Syndromes , 1996 .
[9] A. Gurney,et al. Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17* , 2003, The Journal of Biological Chemistry.
[10] J. Banchereau,et al. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes , 1996, The Journal of experimental medicine.
[11] Y. Ilan,et al. Induction of immune tolerance: a role for Natural killer T lymphocytes? , 2005, Liver international : official journal of the International Association for the Study of the Liver.
[12] J. Banchereau,et al. Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA. , 1994, The Journal of clinical investigation.
[13] P. Berman,et al. Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis , 1980, The Journal of experimental medicine.
[14] P. Karachunski,et al. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. , 2000, Journal of immunology.
[15] K. Bergström,et al. Acetylcholine Receptor Antibody in Myasthenia Gravis: Purification and Characterization , 1978, Scandinavian journal of immunology.
[16] J. Howard,et al. CD4+ T cell response to the human acetylcholine receptor alpha subunit in myasthenia gravis. A study with synthetic peptides. , 1990, Journal of immunology.
[17] K. Rajewsky,et al. Generation and analysis of interleukin-4 deficient mice. , 1991, Science.
[18] P. Christadoss. Immunogenetics of experimental autoimmune myasthenia gravis. , 1989, Critical reviews in immunology.
[19] L. Moiola,et al. Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor. , 1992, The Journal of clinical investigation.
[20] V. Nussenzweig,et al. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids , 1987, The Journal of experimental medicine.
[21] P. Christadoss,et al. Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis , 2002, Journal of Neuroimmunology.
[22] R. Locksley,et al. Altered Immune Responses in Interleukin 10 Transgenic Mice , 1997, The Journal of experimental medicine.
[23] L. Steinman,et al. CD4+ T-cell subsets in autoimmunity. , 1997, Current opinion in immunology.
[24] F. Shi,et al. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. , 2000, International immunology.
[25] H. Link,et al. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. , 1999, Journal of immunology.
[26] D Elmqvist. Myasthenia Gravis , 1975, The Lancet.
[27] N. Calcutt,et al. Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction , 1995, The Journal of experimental medicine.
[28] T. Mosmann,et al. IL-10, a novel growth cofactor for mature and immature T cells. , 1990, Journal of immunology.
[29] M. Shenoy,et al. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. , 1994, Journal of immunology.
[30] M. Atassi,et al. T lymphocyte recognition of acetylcholine receptor: Localization of the full T cell recognition profile on the extracellular part of the α chain of Torpedo californica acetylcholine receptor , 1987, European journal of immunology.
[31] J. Lindstrom,et al. Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs , 1975, The Journal of experimental medicine.
[32] P. Karachunski,et al. Absence of IFN-γ or IL-12 Has Different Effects on Experimental Myasthenia Gravis in C57BL/6 Mice1 , 2000, The Journal of Immunology.
[33] N. Sarvetnick,et al. Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ , 1990, Nature.
[34] P. Christadoss. C5 gene influences the development of murine myasthenia gravis. , 1988, Journal of immunology.
[35] D. Alarcón-Segovia,et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus , 1995, The Journal of experimental medicine.
[36] V. Oliveira,et al. IFN-γ production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo , 2005, The Journal of experimental medicine.
[37] S. Fuchs,et al. Overexpression of IFN-Induced Protein 10 and Its Receptor CXCR3 in Myasthenia Gravis1 , 2005, The Journal of Immunology.
[38] J. O’Shea. Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? , 1997, Immunity.
[39] S. Komoly,et al. Myasthenia gravis: demonstration of membrane attack complex in muscle end-plates. , 1986, Clinical neuropathology.
[40] P. Christadoss,et al. The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. , 1998, Journal of immunology.
[41] D. Carvajal,et al. IL-12-Deficient Mice Are Defective in IFNγ Production and Type 1 Cytokine Responses , 1996 .
[42] J. Link. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. , 1994, Acta neurologica Scandinavica. Supplementum.
[43] R. Hirsch,et al. EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON , 1987, The Lancet.
[44] S. Nakae,et al. Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice 1 , 2003, The Journal of Immunology.
[45] Ethan M. Shevach,et al. CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.
[46] G. Bulkley,et al. Myasthenia Gravis: The Immunobiology of an Autoimmune Disease , 1998 .
[47] P. Christadoss,et al. Immunotherapy for myasthenia gravis: a murine model. , 1986, Journal of immunology.
[48] G. Comi,et al. IL‐12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody‐ mediated disease , 1998, European journal of immunology.
[49] Brigitta Stockinger,et al. Differentiation and function of Th17 T cells. , 2007, Current opinion in immunology.
[50] J. Atkinson,et al. Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. , 1989, The Journal of clinical investigation.
[51] M. Roncarolo,et al. Type 1 T regulatory cells , 2001, Immunological reviews.
[52] J. Banchereau,et al. Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. , 1995, International immunology.
[53] M. Milani,et al. The Susceptibility to Experimental Myasthenia Gravis of STAT6−/− and STAT4−/− BALB/c Mice Suggests a Pathogenic Role of Th1 Cells 1 , 2004, The Journal of Immunology.
[54] H. P. Benton,et al. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus , 1999, Inflammation Research.
[55] J. Banchereau,et al. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. , 1995, Journal of immunology.
[56] C. Hsieh,et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.
[57] R. Caspi,et al. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-γ are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. , 2007, The Journal of Immunology.
[58] C. Chan,et al. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. , 1997, Journal of immunology.
[59] S. Fuchs,et al. Strain differences in the autoimmune response of mice to acetylcholine receptors , 1976, Nature.
[60] W. Cowden,et al. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. , 1996, Journal of immunology.
[61] I. Macpherson. CANCER IMMUNOCHEMOTHERAPY: THE ROLE OF IMMUNOSTIMULATION , 1974 .
[62] M. David,et al. Impaired Development of CD4+ CD25+ Regulatory T Cells in the Absence of STAT1 , 2004, The Journal of experimental medicine.
[63] J. Wolinsky,et al. Immune studies in human immunodeficiency virus infection with myasthenia gravis , 1990, Neurology.
[64] A. Levinson,et al. In vitro synthesis of antibodies to acetylcholine receptor by peripheral blood cells , 1984, Neurology.
[65] J. Howard,et al. T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis , 2000, Journal of Neuroimmunology.
[66] H. Weiner,et al. Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals , 1994, European journal of immunology.
[67] C. Akdis,et al. IL‐10‐induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[68] Mark Ellisman,et al. Proteolytic nicking of the acetylcholine receptor. , 1980, Biochemistry.
[69] A. Engel,et al. Ultrastructural Localization of the Terminal and Lytic Ninth Complement Component (C9) at the Motor End‐plate in Myasthenia Gravis , 1979, Journal of neuropathology and experimental neurology.
[70] L. Moiola,et al. Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects. , 1994, The Journal of clinical investigation.
[71] K. Matsushima,et al. T helper 2 cytokines differently regulate monocyte chemoattractant protein-1 production by human peripheral blood monocytes and alveolar macrophages. , 1996, Journal of immunology.
[72] J. D. de Vries,et al. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. , 1998, Journal of immunology.
[73] M. Battaglia,et al. The puzzling world of murine T regulatory cells. , 2002, Microbes and infection.
[74] M. Shenoy,et al. Effect of MHC class I and CD8 cell deficiency on experimental autoimmune myasthenia gravis pathogenesis. , 1994, Journal of immunology.
[75] A. Bradley,et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. , 1993, Science.
[76] R. Pirskanen,et al. Acetylcholine receptor-reactive T cells in myasthenia gravis: Evidence for the involvement of different subpopulations of T helper cells , 1994, Journal of Neuroimmunology.
[77] J. Kapp,et al. Fine-specificity differences in the recognition of an encephalitogenic peptide by T helper 1 and 2 cells , 1993, Journal of Neuroimmunology.
[78] P. Charukamnoetkanok,et al. IFN-gamma increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. , 1999, Journal of immunology.
[79] P. Berman,et al. Experimental myasthenia gravis. A murine system , 1980, The Journal of experimental medicine.
[80] N. Harindranath,et al. CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line. , 1998, Journal of immunology.
[81] F. Shi,et al. Role for Interferon-γ in Rat Strains with Different Susceptibility to Experimental Autoimmune Myasthenia Gravis , 2000 .
[82] J. Howard,et al. Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[83] Samir A. Shah,et al. T Cell–mediated Pathology in Two Models of Experimental Colitis Depends Predominantly on the Interleukin 12/Signal Transducer and Activator of Transcription (Stat)-4 Pathway, but Is Not Conditional on Interferon γ Expression by T Cells , 1998, The Journal of experimental medicine.
[84] M. Kronenberg,et al. Going both ways: immune regulation via CD1d-dependent NKT cells. , 2004, The Journal of clinical investigation.
[85] M. Bellone,et al. Experimental myasthenia gravis in congenic mice. Sequence mapping and H‐2 restriction of T helper epitopes on the α subunits of Torpedo californica and murine acetylcholine receptors , 1991, European journal of immunology.
[86] P. Christadoss,et al. Resistance to Experimental Autoimmune Myasthenia Gravis in IL-6-Deficient Mice Is Associated with Reduced Germinal Center Formation and C3 Production1 , 2002, The Journal of Immunology.
[87] A. Vincent,et al. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis , 1996, Journal of Neuroimmunology.
[88] R. Caspi,et al. C57BL/6 Mice Genetically Deficient in IL-12/IL-23 and IFN-γ Are Susceptible to Experimental Autoimmune Myasthenia Gravis, Suggesting a Pathogenic Role of Non-Th1 Cells1 , 2007, Journal of Immunology.
[89] R. J. Hocking,et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.
[90] R. Hohlfeld,et al. Induction of HLA-DR expression on human myoblasts with interferon-gamma. , 1990, The American journal of pathology.
[91] G. Biesecker,et al. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. , 1989, Journal of immunology.
[92] A. Billiau,et al. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. , 1994, Journal of immunology.
[93] A. Levinson,et al. Suppressor T cells in myasthenia gravis and antibodies to acetylcholine receptor , 1986, Annals of neurology.
[94] J. Lindstrom,et al. EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS: CELLULAR AND HUMORAL IMMUNE RESPONSES * , 1976, Annals of the New York Academy of Sciences.
[95] A. Zlotnik,et al. IL-10: a novel cytotoxic T cell differentiation factor. , 1991, Journal of immunology.
[96] M. Shenoy,et al. The pathogenic role of acetylcholine receptor α chain epitope within α146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice , 1994 .
[97] M. Leach,et al. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. , 1998, Journal of immunology.
[98] L. Moiola,et al. Myasthenia gravis: Residues of the α and γ subunits of muscle acetylcholine receptor involved in formation of immunodominant CD4+ epitopes , 1994 .
[99] H. Müller-Hermelink,et al. Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. , 1988, The Journal of clinical investigation.
[100] H. Mcdevitt,et al. In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[101] A. Engel,et al. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. , 1977, Mayo Clinic proceedings.
[102] H. Weiner,et al. Antigen-driven peripheral immune tolerance: suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. , 1996, Cellular immunology.
[103] A. Saoudi,et al. Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses1 , 2005, The Journal of Immunology.
[104] S. Youssef,et al. Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. , 1998, Journal of immunology.
[105] A. Billiau,et al. Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-γ , 2005, Arthritis research & therapy.
[106] A. Roberts,et al. Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. , 1998, Journal of immunology.
[107] P. Christadoss,et al. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR , 2000, Journal of Neuroimmunology.
[108] Zeng-Yu Wang,et al. T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis , 1998, Neurology.
[109] J. Howard,et al. CD4+ T‐epitope repertoire on the human acetylcholine receptor α subunit in severe myasthenia gravis , 1992, Neurology.
[110] P. Christadoss,et al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia , 2006, The Journal of Immunology.
[111] C. Harris,et al. Tissue distribution of products of the mouse decay‐accelerating factor (DAF) genes. Exploitation of a Daf1 knock‐out mouse and site‐specific monoclonal antibodies , 2001, Immunology.
[112] L. Harrison,et al. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. , 1991, The Journal of clinical investigation.
[113] H. Kaminski,et al. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. , 2002, The Journal of clinical investigation.
[114] S. Romagnani,et al. The Th1/Th2 paradigm. , 1997, Immunology today.
[115] S. Dunn,et al. Functional stability of Torpedo acetylcholine receptor. Effects of protease treatment. , 1982, Biochemistry.
[116] P. Christadoss,et al. Role of IL-5 during primary and secondary immune response to acetylcholine receptor , 2002, Journal of Neuroimmunology.
[117] Zeng-Yu Wang,et al. Thl epitope repertoire on the a subunit of human muscle acetylcholine receptor in myasthenia gravis , 1997, Neurology.
[118] J. Howard,et al. T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits. , 1993, The Journal of clinical investigation.
[119] Zeng-Yu Wang,et al. T Cell Recognition of the Acetylcholine Receptor in Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.
[120] R. Ulevitch,et al. Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis , 1978, The Journal of experimental medicine.
[121] J. Banchereau,et al. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3 , 1994, The Journal of experimental medicine.
[122] N. Sarvetnick,et al. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. , 1990, Nature.
[123] P. Karachunski,et al. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. , 1997, The Journal of clinical investigation.
[124] P. Christadoss,et al. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. , 2002, The Journal of clinical investigation.
[125] P. Limburg,et al. Anti-acetylcholine receptor antibodies in myasthenia gravis Part 1. Relation to clinical parameters in 250 patients , 1983, Journal of the Neurological Sciences.
[126] P. Karachunski,et al. Nasal Administration of Synthetic Acetylcholine Receptor T Epitopes Affects the Immune Response to the Acetylcholine Receptor and Prevents Experimental Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.
[127] S. Nakae,et al. IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.
[128] S. Akira,et al. STAT family of transcription factors in cytokine-mediated biological responses. , 2000, Cytokine & growth factor reviews.
[129] A. Vincent,et al. Anti-acetylcholine receptor antibodies. , 1980, Journal of neurology, neurosurgery, and psychiatry.
[130] Xiaojian Huang,et al. Genetic Absence of γ-Interferon Delays but Does Not Prevent Diabetes in NOD Mice , 1996, Diabetes.
[131] Th1/Th2 cells. , 1999, Inflammatory bowel diseases.
[132] R. Hohlfeld,et al. Autoimmune human T lymphocytes specific for acetylcholine receptor , 1984, Nature.
[133] M. Toda,et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.
[134] Kenneth M. Murphy,et al. Functional diversity of helper T lymphocytes , 1996, Nature.
[135] M. Raftery,et al. The nicotinic acetylcholine receptor: structure and autoimmune pathology. , 1994, Critical reviews in biochemistry and molecular biology.
[136] M. Kronenberg,et al. Transgenic Expression of IL-10 in T Cells Facilitates Development of Experimental Myasthenia Gravis1 , 2001, The Journal of Immunology.
[137] L. Rassenti,et al. HLA-DQ BETA-CHAIN POLYMORPHISM LINKED TO MYASTHENIA GRAVIS , 1986, The Lancet.
[138] H. Weiner,et al. Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells , 2001, Immunological reviews.
[139] J. Lafaille. The role of helper T cell subsets in autoimmune diseases. , 1998, Cytokine & growth factor reviews.
[140] Zeng-Yu Wang,et al. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes , 1999, Neurology.
[141] J. Dichgans,et al. Ocular myasthenia gravis , 1993, Documenta Ophthalmologica.
[142] S. Constant,et al. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.
[143] L. Chen,et al. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. , 1995, Journal of immunology.
[144] R. Hirsch,et al. Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.
[145] P. Christadoss,et al. GENETIC CONTROL OF AUTOIMMUNITY TO ACETYLCHOLINE RECEPTORS: ROLE OF Ia MOLECULES * , 1981, Annals of the New York Academy of Sciences.
[146] J. Bromberg,et al. IL-10 immunosuppression in transplantation. , 1995, Current opinion in immunology.
[147] G. Trinchieri,et al. B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation , 1994, The Journal of experimental medicine.
[148] L. Steinman,et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). , 1996, Journal of immunology.
[149] S. Fuchs,et al. Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. , 1999, The Journal of clinical investigation.
[150] A. Saoudi,et al. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. , 2005, Blood.
[151] P. Karachunski,et al. Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor , 1999, Journal of Neuroimmunology.
[152] T. Olsson,et al. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats , 1995, European journal of immunology.
[153] R. Longhi,et al. Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. , 1999, The Journal of clinical investigation.
[154] Shizuo Akira,et al. Functional Roles of STAT Family Proteins: Lessons from Knockout Mice , 1999, Stem cells.
[155] A. Lindén,et al. Interleukin-17 family members and inflammation. , 2004, Immunity.
[156] M. Veldhoen,et al. TGFbeta1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells. , 2006, Trends in immunology.
[157] P. Bedossa,et al. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. , 1991, Journal of autoimmunity.
[158] F. Clementi,et al. Cellular immune response to acetylcholine receptor in myasthenia gravis , 1979, Neurology.
[159] J. Lindstrom,et al. Adoptive protection from experimental myasthenia gravis with T cells from mice treated nasally with acetylcholine receptor epitopes , 2002, Journal of Neuroimmunology.
[160] M. Seldin,et al. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. , 1995, Journal of immunology.
[161] J. Howard,et al. Human thymuses express incomplete sets of muscle acetylcholine receptor subunit transcripts that seldom include the δ subunit , 2001, Muscle & nerve.
[162] N. Dybdal,et al. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. , 1996, Diabetes.
[163] T. Olsson,et al. Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis , 1996, The Journal of experimental medicine.
[164] M. Milani,et al. Absence of IL-4 Facilitates the Development of Chronic Autoimmune Myasthenia Gravis in C57BL/6 Mice1 , 2003, The Journal of Immunology.
[165] M. Davisson,et al. The mouse mutation severe combined immune deficiency (scid) is on chromosome 16 , 2006, Immunogenetics.
[166] Link,et al. Increased levels of circulating acetylcholine receptor (AChR)‐reactive IL‐10‐secreting cells are characteristic for myasthenia gravis (MG) , 1999, Clinical and experimental immunology.
[167] L. Moiola,et al. Immunoregulatory CD8+ cells recognize antigen-activated CD4+ cells in myasthenia gravis patients and in healthy controls. , 1995, Journal of immunology.
[168] L. Moiola,et al. Myasthenia gravis. T epitopes on the delta subunit of human muscle acetylcholine receptor. , 1991, Journal of immunology.
[169] S. Meri,et al. Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. , 1991, Laboratory investigation; a journal of technical methods and pathology.
[170] M. Bosma,et al. Defective V‐to‐J recombination of T cell receptor γ chain genes in scid mice , 1990, European journal of immunology.
[171] S. Fuchs,et al. Role of Tolerogen Conformation in Induction of Oral Tolerance in Experimental Autoimmune Myasthenia Gravis1 , 2000, The Journal of Immunology.